SYBX - Synlogic Inc Stock Price, Fair Value and News

1.88USD-0.02 (-1.05%)Market Closed

Market Summary

USD1.88-0.02

Market Closed

-1.05%

SYBX Stock Price

View Fullscreen

SYBX RSI Chart

SYBX Valuation

Market Cap

21.9M

Price/Earnings (Trailing)

-0.38

Price/Sales (Trailing)

6.48

EV/EBITDA

0.04

Price/Free Cashflow

-0.42

SYBX Price/Sales (Trailing)

SYBX Profitability

EBT Margin

-1698.84%

Return on Equity

-134.29%

Return on Assets

-75.82%

Free Cashflow Yield

-237.1%

SYBX Fundamentals

SYBX Revenue

Revenue (TTM)

3.4M

Rev. Growth (Yr)

202.11%

Rev. Growth (Qtr)

187.25%

SYBX Earnings

Earnings (TTM)

-57.3M

Earnings Growth (Yr)

12.95%

Earnings Growth (Qtr)

-20.33%

Breaking Down SYBX Revenue

Last 7 days

1.1%

Last 30 days

6.8%

Last 90 days

-44.9%

Trailing 12 Months

-76.7%

How does SYBX drawdown profile look like?

SYBX Financial Health

Current Ratio

2.45

SYBX Investor Care

Shares Dilution (1Y)

156.32%

Diluted EPS (TTM)

-8.81

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.7M	2.2M	2.3M	3.4M
2022	1.8M	1.7M	1.2M	1.2M
2021	854.8K	1.2M	1.5M	1.8M
2020	2.5M	2.5M	2.4M	545.0K
2019	2.5M	2.6M	1.1M	2.2M
2018	2.7M	830.0K	2.5M	2.5M
2017	444.0K	2.4M	2.4M	2.4M
2016	0	0	0	444.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Synlogic Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	dooley mary beth	sold	-325	1.73	-188	head of finance
Apr 02, 2024	awad antoine	sold	-643	1.73	-372	chief operating officer
Apr 03, 2023	awad antoine	sold	-3,707	0.5758	-6,438	chief operating officer
Apr 03, 2023	brennan aoife	sold	-10,964	0.5758	-19,042	see remarks
Apr 03, 2023	jensen michael vangsted	sold	-1,470	0.5758	-2,553	chief financial officer
May 24, 2022	jensen michael vangsted	bought	10,640	1.12	9,500	chief financial officer
Apr 04, 2022	brennan aoife	sold	-21,753	2.4459	-8,894	see remarks
Apr 04, 2022	awad antoine	sold	-6,481	2.4459	-2,650	chief operating officer
Mar 03, 2022	jensen michael vangsted	acquired	-	-	30,000	chief financial officer
Feb 04, 2022	brennan aoife	acquired	-	-	106,920	see remarks

Which funds bought or sold SYBX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-1,309	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	25.98	305,172	725,467	-%
Mar 08, 2024	ICA Group Wealth Management, LLC	new	-	50.00	50.00	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-30,944	-	-%
Feb 14, 2024	ABG Innovation Capital Partners III GP Ltd	new	-	52,849	52,849	5.87%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	41,811	41,811	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-34.00	-1,000	2,000	-%
Feb 14, 2024	ORBIMED ADVISORS LLC	sold off	-100	-1,129,610	-	-%

Are Funds Buying or Selling SYBX?

Are funds buying SYBX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SYBX

No. of Funds

Unveiling Synlogic Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 18, 2024	radoff bradley louis	5.4%	629,211	SC 13G
Feb 16, 2024	funicular funds, lp	36.0%	3,312,219	SC 13D
Feb 14, 2024	armistice capital, llc	9.99%	1,285,542	SC 13G
Feb 14, 2024	kryzanowski john a	9.51%	873,722	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Oct 13, 2023	fmr llc	-	0	SC 13G/A
Oct 13, 2023	new enterprise associates 14, l.p.	34.4%	2,922,774	SC 13D/A
Oct 10, 2023	fil ltd	-	0	SC 13G/A
Oct 04, 2023	orbimed advisors llc	4.7%	401,998	SC 13D/A
Feb 14, 2023	ra capital management, l.p.	0%	0	SC 13G/A

Recent SEC filings of Synlogic Inc

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	10-K/A	Annual Report
Apr 22, 2024	144	Notice of Insider Sale Intent
Apr 18, 2024	SC 13G	Major Ownership Report
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Mar 21, 2024	144	Notice of Insider Sale Intent
Mar 21, 2024	3	Insider Trading
Mar 21, 2024	3	Insider Trading
Mar 21, 2024	4	Insider Trading
Mar 21, 2024	8-K	Current Report

Peers (Alternatives to Synlogic Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Synlogic Inc News

Latest updates

Synlogic Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	187.2%	1,577,000	549,000	617,000	628,000	522,000	422,000	169,000	67,000	562,000	916,000	246,000	60,000	138,000	216,000	406,000	574,000	1,231,000	305,000	350,000	338,000	111,000
Operating Expenses	3.0%	13,410,000	13,016,000	15,689,000	16,417,000	17,409,000	19,012,000	16,169,000	16,009,000	15,737,000	16,971,000	14,780,000	15,031,000	14,694,000	13,437,000	16,382,000	16,498,000	14,710,000	14,443,000	13,445,000	14,035,000	12,819,000
S&GA Expenses	-3.8%	3,270,000	3,400,000	3,924,000	3,967,000	3,770,000	4,402,000	4,112,000	4,271,000	3,864,000	3,616,000	4,061,000	3,851,000	3,287,000	2,956,000	3,473,000	3,821,000	3,456,000	3,879,000	3,742,000	3,651,000	3,952,000
R&D Expenses	5.4%	10,140,000	9,616,000	11,765,000	12,450,000	13,639,000	14,610,000	12,057,000	11,738,000	11,873,000	13,355,000	10,719,000	11,180,000	11,407,000	10,481,000	12,909,000	12,677,000	11,254,000	10,564,000	9,703,000	10,384,000	8,867,000
EBITDA Margin	40.6%	-16.41	-27.62	-29.14	-36.56	-53.92	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	1,000	-1,000	1,000	1,000	1,000	-	1,000	1,000	-	-	1,000	2,000	3,000	4,000	5,000	5,000	7,000	7,000
Income Taxes	-33.3%	2,000	3,000	9,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-20.3%	-14,532,000	-12,075,000	-15,039,000	-	-	-17,912,000	-15,842,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	40.5%	-16.99	-28.56	-30.22	-37.99	-56.06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-20.3%	-14,534,000	-12,078,000	-15,048,000	-15,622,000	-16,696,000	-17,912,000	-15,842,000	-15,697,000	-15,089,000	-16,016,000	-14,485,000	-14,971,000	-14,588,000	-13,222,000	-15,535,000	-15,828,000	-12,798,000	-13,285,000	-12,344,000	-12,946,000	-11,931,000
Net Income Margin	33.8%	-16.99	-25.67	-29.82	-37.95	-56.06	-52.90	-36.55	-34.22	-33.95	-40.74	-49.18	-68.23	-	-	-	-	-	-	-	-	-
Free Cashflow	57.1%	-5,556,000	-12,955,000	-11,669,000	-21,648,000	-12,436,000	-15,505,000	-13,721,000	-15,954,000	-13,232,000	-14,201,000	-11,447,000	-13,997,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	14.0%	76.00	66.00	79.00	93.00	111	128	144	159	175	191	157	136	144	148	159	171	189	202	215	145	140
Current Assets	32.1%	50.00	38.00	50.00	62.00	80.00	97.00	111	124	133	157	123	101	107	111	122	127	133	131	163	114	124
Cash Equivalents	-2.3%	24.00	25.00	46.00	26.00	16.00	16.00	31.00	21.00	16.00	63.00	29.00	27.00	33.00	27.00	31.00	19.00	26.00	27.00	17.00	16.00	11.00
Net PPE	-5.8%	6.00	6.00	6.00	7.00	7.00	8.00	8.00	9.00	9.00	10.00	10.00	10.00	11.00	11.00	12.00	13.00	13.00	13.00	14.00	14.00	15.00
Current Liabilities	123.1%	20.00	9.00	10.00	10.00	12.00	12.00	9.00	10.00	10.00	11.00	10.00	7.00	8.00	7.00	6.00	7.00	9.00	10.00	11.00	10.00	8.00
Shareholder's Equity	-1.7%	43.00	43.00	55.00	69.00	83.00	100	117	132	147	162	128	109	115	120	132	142	157	169	181	112	124
Retained Earnings	-3.6%	-414	-399	-387	-372	-357	-340	-322	-306	-290	-275	-259	-245	-230	-215	-202	-186	-171	-158	-145	-132	-119
Additional Paid-In Capital	3.1%	459	446	445	444	442	441	440	439	438	437	388	354	345	336	334	329	328	327	326	245	244
Accumulated Depreciation	-	14.00	-	-	-	13.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	99.8%	9.00	5.00	5.00	5.00	4.00	5.00	5.00	5.00	5.00	4.00	3.00	3.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	24.00	-	-	-	42.00	-	-	-	122	-	-	-	38.00	-	-	-	162	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	57.3%	-5,528	-12,955	-11,626	-21,505	-12,393	-15,449	-13,569	-15,477	-13,060	-13,817	-11,345	-13,976	-9,888	-8,198	-8,988	-12,479	-11,214	-10,550	-40,586	-13,118	-8,963
Share Based Compensation	25.5%	803	640	645	718	878	894	977	890	800	808	876	877	802	935	1,075	1,095	1,026	1,069	1,100	954	873
Cashflow From Investing	-65.6%	-14,628	-8,832	31,959	30,270	14,861	119	23,613	19,758	-33,307	-1,355	-18,745	154	7,109	2,458	17,098	5,817	10,009	20,619	-37,507	17,675	2,917
Cashflow From Financing	31480.6%	19,580	62.00	389	913	-2,229	51.00	6.00	132	-120	48,853	32,630	8,019	8,471	1,205	3,787	-69.00	-69.00	-53.00	79,791	-65.00	44.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SYBX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 3,371	$ 1,180
Operating expenses:
Research and development	43,971	52,044
General and administrative	14,561	16,555
Total operating expenses	58,532	68,599
Loss from operations	(55,161)	(67,419)
Other income (expense):
Interest and investment income	2,469	1,267
Interest expense	(1)	(2)
Loss on purchase warrant liabilities	(4,058)	0
Other expense	(517)	7
Other income (expense), net	(2,107)	1,272
Loss before income taxes	(57,268)	(66,147)
Income tax expense	(14)	0
Net loss	$ (57,282)	$ (66,147)
Net loss per share - basic and diluted	$ (8.81)	$ (13.83)
Net loss per share - basic and diluted	$ (8.81)	$ (13.83)
Weighted-average common stock outstanding - basic and diluted	6,502,279	4,781,696
Weighted-average common stock outstanding - basic and diluted	6,502,279	4,781,696
Comprehensive loss:
Net Income (Loss)	$ (57,282)	$ (66,147)
Net unrealized gain (loss) on marketable securities	167	(116)
Comprehensive loss	$ (57,115)	$ (66,263)

SYBX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 23,960	$ 15,861
Short-term marketable securities	23,786	61,768
Prepaid expenses and other current assets	2,161	2,153
Total current assets	49,907	79,782
Property and equipment, net	5,603	7,323
Right of use asset - operating lease	12,102	14,356
Restricted cash	1,097	1,097
Prepaid research and development, net of current portion	6,825	8,300
Other assets	16	7
Total assets	75,550	110,865
Current liabilities:
Accounts payable	1,457	1,785
Accrued expenses	3,000	5,290
Deferred revenue	0	882
Lease liability - operating lease	4,780	4,152
Finance lease obligations	4	13
Purchase warrant laibility	11,163	0
Total current liabilities	20,404	12,122
Long-term liabilities:
Lease liability - operating lease, net of current portion	12,491	16,129
Finance lease obligations, net of current portion	0	4
Total long-term liabilities	12,491	16,133
Commitments and contingencies (Note 14)
Stockholders' equity
Common stock, $0.001 par value 250,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 9,465,949 shares issued and 9,186,157 shares outstanding as of December 31, 2023 and 4,728,874 shares issued and 4,449,082 outstanding as of December 31, 2022	10	5
Additional paid-in capital	459,458	442,303
Accumulated other comprehensive income (loss)	6	(161)
Accumulated deficit	(414,301)	(357,019)
Treasury stock, at cost (279,792 shares at December 31, 2023 and at December 31, 2022)	(2,518)	(2,518)
Total stockholders' equity	42,655	82,610
Total liabilities and stockholders' equity	$ 75,550	$ 110,865

About Synlogic Inc

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

CEO	Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
WEBSITE	synlogictx.com
INDUSTRY	Biotechnology
EMPLOYEES	72

Synlogic Inc Frequently Asked Questions

What is the ticker symbol for Synlogic Inc? What does SYBX stand for in stocks?

SYBX is the stock ticker symbol of Synlogic Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Synlogic Inc (SYBX)?

As of Thu May 02 2024, market cap of Synlogic Inc is 21.86 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SYBX stock?

You can check SYBX's fair value in chart for subscribers.

What is the fair value of SYBX stock?

You can check SYBX's fair value in chart for subscribers. The fair value of Synlogic Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Synlogic Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SYBX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Synlogic Inc a good stock to buy?

The fair value guage provides a quick view whether SYBX is over valued or under valued. Whether Synlogic Inc is cheap or expensive depends on the assumptions which impact Synlogic Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SYBX.

What is Synlogic Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, SYBX's PE ratio (Price to Earnings) is -0.38 and Price to Sales (PS) ratio is 6.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SYBX PE ratio will change depending on the future growth rate expectations of investors.